Professionelle Dienstleistungen Schweiz

Kodiak Sciences News

Aktie
WKN:  A2N6P0 ISIN:  US50015M1099 US-Symbol:  KOD
2,95 €
-0,06 €
-1,99%
21.05.24 21:07:18
Handeln Depot/Watchlist
Aktienanzahl *
52,25 Mio.
Marktkapitalisierung *
157,37 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 02.06.2023

Kodiak Sciences News

15.05.24 - PR Newswire
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire
13.05.24 - PR Newswire
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire
02.05.24 - PR Newswire
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-​Phase Retina Pipeline including Advancements with High Drug-​Antibody-Ratio Therapeutics Built on Kodiak's ...
28.03.24 - PR Newswire
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results PR Newswire
26.03.24 - PR Newswire
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 PR Newswire
30.01.24 - PR Newswire
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting ...
04.01.24 - PR Newswire
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
21.11.23 - PR Newswire
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire
14.11.23 - PR Newswire
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights PR Newswire
06.11.23 - PR Newswire
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory ...
01.11.23 - PR Newswire
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH ...
11.10.23 - PR Newswire
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society PR Newswire
08.09.23 - PR Newswire
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference PR Newswire
07.09.23 - PR Newswire
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and ...
18.08.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD PR Newswire
14.08.23 - PR Newswire
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights PR Newswire
10.08.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD PR Newswire
04.08.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD PR Newswire
26.07.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD PR Newswire
24.07.23 - PR Newswire
Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program
Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-​Related Macular Degeneration and Diabetic Macular Edema ...

Newssuche

Videos

08:45 Uhr +3,67%
Technical Trading: Sojabohnen im saisonalen Trend
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »